参考文献
[1]Jordan T,Mastnak DM,Palamar N,et al.Nutritional Therapy for Patients with Esophageal Cancer[J].Nutr Cancer,2018,70(1):23-29.
[2]van Hagen P,Hulshof MC,van Lanschot JJ,et al.Preoperative chemoradiotherapy for esophageal orjunctional cancer[J].N Engl J Med,2012,366(22):2074-2084.
[3]Goense L,van Rossum PS,Kandioler D,et al.Stage-directed individualized therapy in esophageal cancer[J].Ann N Y Acad Sci,2016,1381(1):50-65.
[4]Wang DK,Zuo Q,He QY,et al.Targeted Immunotherapies in Gastrointestinal Cancer:From Molecular Mechanisms to Implications[J].Front Immunol,2021,12:705999.
[5]Grieb BC,Agarwal R.HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma:Triumphs and Troubles[J].Curr Treat Options Oncol,2021,22(10):88.
[6]Due SL,Watson DI,Hussey DJ.Oestrogen receptors:A potential therapeutic target in oesophageal adenocarcinoma?[J].ANZ J Surg,2021,91(7-8):1390-1396.
[7]Anderson LA,Tavilla A,Brenner H,et al.Survival for oesophageal,stomach and small intestine cancers in Europe 1999-2007:Results from EUROCARE-5[J].Eur J Cancer,2015,51(15):2144-2157.
[8]Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:a population-based study[J].Int J Cancer,2015,136(8):1921-1930.
[9]Grille VJ,Campbell S,Gibbs JF,et al.Esophageal cancer:the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt[J].J Gastrointest Oncol,2021,12(Suppl 2):S339-S349.
[10]Zhang GQ,Han F,Sun W,et al.[Impact of different extents of lymph node dissection on the survival in stage Ⅲ esophageal cancer patients][J].Zhonghua Zhong Liu Za Zhi,2008,30(11):858-862.
[11]Yuan LG,Mao YS.[Thoracic recurrent laryngeal nerve lymph node metastasis guides the cervical lymph node dissection of patients with esophageal cancer][J].Zhonghua Zhong Liu Za Zhi,2019,41(1):10-14.
[12]Han WH,Eom BW,Yoon HM,et al.The optimal extent of lymph node dissection in gastroesophageal junctional cancer:retrospective case control study[J].BMC Cancer,2019,19(1):719.
[13]Oh SE,Lee GH,An JY,et al.Comparison of transabdominal and transthoracic surgical approaches in the treatment of Siewert type Ⅱ esophagogastric junction cancers:A propensity score-matching analysis[J].Eur J Surg Oncol,2022,48(2):370-376.
[14]Yamashita H,Seto Y,Sano T,et al.Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma[J].Gastric Cancer,2017,20(Suppl 1):69-83.
[15]Imamura Y,Watanabe M,Oki E,et al.Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma:Literature review and retrospective multicenter cohort study[J].Ann Gastroenterol Surg,2021,5(1):46-59.
[16]Wang Y,Zhu L,Xia W,et al.Anatomy of lymphatic drainage of the esophagus and lymph node metastasis of thoracic esophageal cancer[J].Cancer Manag Res,2018,10:6295-6303.
[17]Xu L,Chen XK,Xie HN,et al.Treatment and Prognosis of Resectable Cervical Esophageal Cancer:A Population-Based Study[J].Ann Thorac Surg,2022,113(6):1873-1881.
[18]Kurtom S,Kaplan BJ.Esophagus and Gastrointestinal Junction Tumors[J].Surg Clin North Am,2020,100(3):507-521.
[19]Noordman BJ,Wijnhoven BPL,Lagarde SM,et al.Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer:a stepped-wedge cluster randomised trial[J].BMC Cancer,2018,18(1):142.
[20]Ho F,Torphy RJ,Friedman C,et al.Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma[J].Ann Surg Oncol,2021,28(12):7208-7218.
[21]Engel S,Awerbuch A,Kwon D,et al.Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer:a meta-analysis[J].J Gastrointest Oncol,2019,10(3):391-399.
[22]Tsai TC,Miller J,Andolfi C,et al.Surgical evaluation of lymph nodes in esophageal adenocarcinoma:Standardized approach or personalized medicine?[J].Eur J Surg Oncol,2018,44(8):1177-1180.(https://www.daowen.com)
[23]Jung MK,Schmidt T,Chon SH,et al.Current surgical treatment standards for esophageal and esophagogastric junction cancer[J].Ann N Y Acad Sci,2020,1482(1):77-84.
[24]Parry K,Haverkamp L,Bruijnen RC,et al.Staging of adenocarcinoma of the gastroesophageal junction[J].Eur J Surg Oncol,2016,42(3):400-406.
[25]Mine S,Watanabe M,Kumagai K,et al.Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction[J].Dis Esophagus,2019,32(11):doz002.
[26]Feith M,Stein HJ,Siewert JR.Adenocarcinoma of the esophagogastric junction:surgical therapy based on 1602 consecutive resected patients[J].Surg Oncol Clin N Am,2006,15(4):751-764.
[27]Kurokawa Y,Hiki N,Yoshikawa T,et al.Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction[J].Surgery,2015,157(3):551-555.
[28]Goto H,Tokunaga M,Miki Y,et al.The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type Ⅱ and Siewert type Ⅲ patients[J].Gastric Cancer,2014,18(2):375-381.
[29]Kakeji Y,Yamamoto M,Ito S,et al.Lymph node metastasis from cancer of the esophagogastric junction,and determination of the appropriate nodal dissection[J].Surg Today,2012,42(4):351-358.
[30]Meier I,Merkel S,Papadopoulos T,et al.Adenocarcinoma of the esophagogastric junction:the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition[J].Int J Radiat Oncol Biol Phys,2008,70(5):1408-1417.
[31]Pedrazzani C,de Manzoni G,Marrelli D,et al.Lymph node involvement in advanced gastroesophageal junction adenocarcinoma[J].J Thorac Cardiovasc Surg,2007,134(2):378-385.
[32]Polkowski WP,van Lanschot JJ.Proximal margin length with transhiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction (Br J Surg 2013;100:1050-1054)[J].Br J Surg,2014,101(6):735.
[33]Ito H,Clancy TE,Osteen RT,et al.Adenocarcinoma of the gastric cardia:what is the optimal surgical approach?[J].J Am Coll Surg,2004,199(6):880-886.
[34]Mariette C,Castel B,Balon JM,et al.Extent of oesophageal resection for adenocarcinoma of the oesophagogastric junction[J].Eur J Surg Oncol,2003,29(7):588-593.
[35]Barbour AP,Rizk NP,Gonen M,et al.Adenocarcinoma of the gastroesophageal junction:influence of esophageal resection margin and operative approach on outcome[J].Ann Surg,2007,246(1):1-8.
[36]Postlewait LM,Squires MH 3rd,Kooby DA,et al.The importance of the proximal resection margin distance for proximal gastric adenocarcinoma:A multi-institutional study of the US Gastric Cancer Collaborative[J].J Surg Oncol,2015,112(2):203-207.
[37]van der Wilk BJ,Eyck BM,Hofstetter WL,et al.Chemoradiotherapy followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer:A Systematic Review and Individual Patient Data Meta-Analysis[J].Ann Surg,2022,275(3):467-476.
[38]Yagi K,Toriumi T,Aikou S,et al.Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma[J].Ann Gastroenterol Surg,2021,5(4):436-445.
[39]Watanabe M,Mine S,Yamada K,et al.Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus[J].Gen Thorac Cardiovasc Surg,2014,62(11):685-692.
[40]Kanamori J,Aokage K,Hishida T,et al.The role of pulmonary resection in tumors metastatic from esophageal carcinoma[J].Jpn J Clin Oncol,2017,47(1):25-31.
[41]Hatogai K,Yano T,Kojima T,et al.Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer[J].Radiat Oncol,2016,11(1):31.
[42]Zhou ZG,Zhen CJ,Bai WW,et al.Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy[J].Radiat Oncol,2015,10(1):54.
[43]Chen Y,Lu Y,Wang Y,et al.Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone[J].Dis Esophagus,2014,27(2):134-140.